SCALE Phase IIIa trial for Saxenda (liraglutide) results in three year weight loss- Novo Nordisk

New data from the phase IIIa SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and Prediabetes three-year trial extension for Saxenda from Novo Nordisk, were presented at Obesity Week 2015, the 3rd annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society. The extension part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline), demonstrated that treatment with Saxenda (liraglutide 3 mg) in combination with a reduced-calorie diet and increased physical activity resulted in significant and sustained weight loss over the three-year span, compared with placebo (reduced-calorie diet and increased physical activity alone).